Insight

Aug 14, 2024, 18:18

Epigenetic and Oncogenic Inhibitors target KRAS-mutant Colorectal Cancers

Elizabeth McKenna shared a post on X about a recent paper by Patrick Loi et al. titled “Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers” published in Cancer Discovery.

Authors: Patrick Loi, Amy Schade, Karen Cichowski et al.

“Now online in Cancer Discovery: Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-mutant Colorectal Cancers – by Patrick Loi, Amy Schade, Karen Cichowski and colleagues.”

Source: Elizabeth McKenna/X

More posts by Elizabeth McKenna in OncoDaily.

Elizabeth McKenna is the Executive Director of Cancer Discovery at the American Association for Cancer Research. Elizabeth earned her PhD from Harvard University and trained with Dr. Charles Roberts at the Dana-Farber Cancer Institute.

Her research was among the first to show that pediatric tumors characterized by mutations in chromatin remodelers are genomically stable and instead driven by epigenetic deregulation of key target genes.

She joined Cancer Discovery shortly after its launch as its founding Science Writer and became an editor in 2014, rising through the editorial ranks to become the journal’s Executive Editor in 2019. She is a member of the 40 Under 40 in Cancer Class of 2021.

AACR Amy Schade cancer Cancer Discovery colorectal cancer Elizabeth McKenna Karen Cichowski KRAS-mutant Colorectal Cancer OncoDaily Oncology Patrick Loi

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer